Mei, Heng Liu, Xiaofan Li, Yan Zhou, Hu Feng, Ying Gao, Guangxun Cheng, Peng Huang, Ruibin Yang, Linhua Hu, Jianda
...
Published in
Journal of Hematology & Oncology
Background Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study aimed to evaluate the efficacy and safety of hetrombopag in ITP patients. Methods Patients who had not responded to or had relapse...
Chen, Timothy L. Harrington, Bonnie Truxall, Jean Wasmuth, Ronni Prouty, Alexander Sloan, Shelby Lehman, Amy M. Sampath, Deepa Orlemans, Eric Baiocchi, Robert A.
...
Published in
Journal of Hematology & Oncology
B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. However patients do still relapse on ibrutinib, and the progressive disease is often quite aggressive requiring immediate treatment. Several s...
Kreitman, Robert J. Dearden, Claire Zinzani, Pier Luigi Delgado, Julio Robak, Tadeusz le Coutre, Philipp D. Gjertsen, Bjørn T. Troussard, Xavier Roboz, Gail J. Karlin, Lionel
...
Published in
Journal of Hematology & Oncology
Background Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here, we present the long-term follow-up analysis of the pivotal, multicenter, open-label trial (NCT01829711) of moxetumomab pasudotox in patients with relapsed/refractory (R/R) hairy cell leukemia (HCL). Methods Eligible patients had received ≥ 2 prior systemic therapies...
Jin, Dan Guo, Jiwei Wu, Yan Du, Jing Yang, Lijuan Wang, Xiaohong Di, Weihua Hu, Baoguang An, Jiajia Kong, Lingqun
...
Published in
Journal of Hematology & Oncology
Zhao, Senlin Mi, Yushuai Guan, Bingjie Zheng, Binbin Wei, Ping Gu, Yanzi Zhang, Zhengxiang Cai, Sanjun Xu, Ye Li, Xinxiang
...
Published in
Journal of Hematology & Oncology
Bolomsky, Arnold Vogler, Meike Köse, Murat Cem Heckman, Caroline A. Ehx, Grégory Ludwig, Heinz Caers, Jo
Published in
Journal of Hematology & Oncology
Yang, Guan-Jun Zhu, Ming-Hui Lu, Xin-Jiang Liu, Yan-Jun Lu, Jian-Fei Leung, Chung-Hang Ma, Dik-Lung Chen, Jiong
Published in
Journal of Hematology & Oncology
Histone methylation is a key posttranslational modification of chromatin, and its dysregulation affects a wide array of nuclear activities including the maintenance of genome integrity, transcriptional regulation, and epigenetic inheritance. Variations in the pattern of histone methylation influence both physiological and pathological events. Lysin...
Liang, Yun Liu, Hui Lu, Zheming Lei, Wen Zhang, Chaoting Li, Ping Liang, Aibin Young, Ken H. Qian, Wenbin
Published in
Journal of Hematology & Oncology
CD19-targeted chimeric antigen receptor T (CAR T) cell therapy is a promising option to treat relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). However, the majority of CAR T-treated patients will eventually progress and require salvage treatment, for which there is no current standard. In this study, we analyzed data from 6 patients w...
Yi, Ming Zhang, Jing Li, Anping Niu, Mengke Yan, Yongxiang Jiao, Ying Luo, Suxia Zhou, Pengfei Wu, Kongming
Published in
Journal of Hematology & Oncology
Background Therapeutic antibodies targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis induce potent and durable anti-tumor responses in multiple types of cancers. However, only a subset of patients benefits from anti-PD-1/PD-L1 therapies. As a negative regulator of anti-tumor immunity, TGF-β impairs the efficacy ...
Ayyappan, Sabarish Maddocks, Kimi
Published in
Journal of Hematology & Oncology
